Compile Data Set for Download or QSAR
maximum 50k data
Found 18 of ic50 data for complexid = 216
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM139540(US10189849, staurosporine | US10307427, Staurospor...)
Affinity DataIC50:  6.18nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622513(US20230312583, Compound I-9)
Affinity DataIC50:  22.5nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622518(US20230312583, Compound I-14)
Affinity DataIC50:  23.9nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622506(US20230312583, Compound I-2)
Affinity DataIC50:  30.9nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622505(US20230312583, Compound I-1)
Affinity DataIC50:  61.8nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622516(US20230312583, Compound I-12)
Affinity DataIC50:  67nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622517(US20230312583, Compound I-13)
Affinity DataIC50:  104nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622515(US20230312583, Compound I-11)
Affinity DataIC50:  116nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622508(US20230312583, Compound I-4)
Affinity DataIC50:  123nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622511(US20230312583, Compound I-7)
Affinity DataIC50:  189nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622509(US20230312583, Compound I-5)
Affinity DataIC50:  214nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622510(US20230312583, Compound I-6)
Affinity DataIC50:  293nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622523(US20230312583, Compound V-1)
Affinity DataIC50:  298nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622519(US20230312583, Compound I-15)
Affinity DataIC50:  330nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622507(US20230312583, Compound I-3)
Affinity DataIC50:  344nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622524(US20230312583, Compound VI-1)
Affinity DataIC50:  388nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622514(US20230312583, Compound I-10)
Affinity DataIC50:  435nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622512(US20230312583, Compound I-8)
Affinity DataIC50: >500nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent